XSNX (Novaccess Global) Research & Development: $0.15 Mil (TTM As of Sep. 2024)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XSNX Novaccess Global Inc XSNX
12 GF Score
Price $0.00
View Full Analysis

What is Novaccess Global Research & Development?

Novaccess Global XSNX 12 Research & Development is $0.15 Mil as of Sep. 2024. GuruFocus rates XSNX with a GF Score™ of 12/100.

Research & Development is the aggregate amount of research and development expenses during the year. Novaccess Global's Research & Development for the three months ended in Sep. 2024 was $0.03 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Sep. 2024 was $0.15 Mil.

Novaccess Global  (OTCPK:XSNX) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Novaccess Global Research & Development Related Terms

Novaccess Global Research & Development Historical Data

* Premium members only.

The historical data trend for Novaccess Global's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Novaccess Global Research & Development Chart

Novaccess Global Annual Data
Trend Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.15 0.19 0.15 0.15

Novaccess Global Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.04 0.05 0.04 0.04 0.03
XSNX
12GF Score
Novaccess Global Inc XSNX
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Novaccess Global Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.15 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of $0.15 Mil mean?
Novaccess Global (XSNX) has a Research & Development of $0.15 Mil as of Sep. 2024. Research and development expense is the total cost for research and development activities. View historical data on Novaccess Global and its competitors.
Is Novaccess Global's Research & Development too high?
Novaccess Global's current Research & Development is $0.15 Mil. Overall, Novaccess Global has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Novaccess Global's Research & Development compare to NBIO and BTAX?
Novaccess Global's Research & Development of $0.15 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Novaccess Global and its competitors. Novaccess Global's current Research & Development is $0.15 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Novaccess Global stock overvalued right now?
Novaccess Global (XSNX) has a current Research & Development of $0.15 Mil. The current Research & Development is $0.15 Mil. Novaccess Global's overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Novaccess Global (XSNX), the current Research & Development is $0.15 Mil as of Sep. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Novaccess Global Business Description

Address 459 Columbus Avenue, No. 607, New York, NY, USA, 10024
Novaccess Global Inc is a biopharmaceutical company that is developing novel immunotherapies to treat brain tumor patients in the United States. The company's team of experts is working to strengthen the capability of the human body's defense against cancer.
12GF Score

Get the complete analysis for XSNX

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price